|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,125,910: Scope, Claims, and Patent Landscape
What Is the Scope of U.S. Patent 9,125,910?
U.S. Patent 9,125,910, titled "Methods of treating cancer," issued August 4, 2015, covers specific methods involving immunotherapeutic combinations for cancer treatment. The patent claims methods that enhance immune response against tumor cells, particularly through administering combinations involving immune checkpoint inhibitors and other therapeutic agents.
Key Aspects of Patent Scope
- Field: Oncology, immunotherapy.
- Therapies covered: Combinations involving PD-1/PD-L1 antibodies and other agents, such as chemotherapy or targeted therapies.
- Claims: Method claims primarily focus on administering a PD-1 or PD-L1 monoclonal antibody with additional agents identified as augmenting anti-tumor immune responses.
What Do the Claims Cover?
The claims of Patent 9,125,910 specify the following:
Main Claims
- Claim 1: A method of treating a cancer by administering an effective dose of a PD-1 or PD-L1 antibody in combination with a second therapeutic agent selected from chemotherapy, radiation therapy, or targeted therapy.
- Claim 2: The combination specifically includes pembrolizumab (Keytruda) or nivolumab (Opdivo) with chemotherapy agents like paclitaxel or carboplatin.
- Claims 3-8: Further specify doses, timing, and particular cancer types, such as non-small cell lung cancer (NSCLC) and melanoma.
Dependent Claims
Add specific combinations, dosages, and treatment schedules, emphasizing particular embodiments involving specific drug dosages and administration intervals.
Scope Limitations
- Focuses on combination treatments involving immunotherapy agents and other cancer therapeutics.
- Applies to multiple cancer types, primarily lung cancer and melanoma.
- The claims are primarily methods-based rather than product claims.
Patent Landscape for Related Immuno-Oncology Patents
Patent Families and Key Competitors
- Major filers include Merck, Bristol-Myers Squibb (BMS), Roche, AstraZeneca, and Novartis.
- Related patents focus on combination therapies involving PD-1/PD-L1 inhibitors, methods of enhancing immune response, and specific formulations or dosing regimens.
Patent Filing Trends
- The patent landscape indicates a surge in filings from 2013-2017, paralleling the clinical development timeline of PD-1/PD-L1 agents.
- A significant portion of patents relates to combination therapies, biomarkers of response, and specific cancer indications.
Patent Expiry and Freedom-to-Operate Considerations
- Many foundational PD-1/PD-L1 patents expire around 2027-2032.
- Claim authorship overlaps with other combination patents, increasing litigation risk and licensing dependencies.
- Specific claims like those in 9,125,910 tend to be narrower, focusing on particular combinations and schedules, which may provide narrower freedom-to-operate margins.
Legal Status and Enforcement
- No significant invalidation or opposition filings have been reported against Patent 9,125,910.
- Potential infringement would involve similar combination methods, especially in lung and melanoma therapies.
Implications for R&D and Licensing
- The patent provides proprietary rights over certain combination treatment methods, offering exclusivity for novel regimens.
- Companies developing immunotherapeutic products should carefully map claims against their combinations to avoid infringement.
- Licensing opportunities may exist in the scope defined by the claims, especially for approved drugs like nivolumab or pembrolizumab combined with chemotherapy.
Summary of Key Data Points
| Aspect |
Details |
| Patent number |
9,125,910 |
| Issue date |
August 4, 2015 |
| Priority date |
December 10, 2012 |
| Expiration date |
Likely December 2032 (assuming 20-year patent term from priority date) |
| Main claimed therapy |
PD-1/PD-L1 antibodies with chemotherapy or other agents |
| Cancer indications |
Lung cancer, melanoma |
| Related drugs |
Nivolumab, pembrolizumab, paclitaxel, carboplatin |
| Patent landscape trend |
Increase filings 2013-2017, focus on combination immunotherapy |
Key Takeaways
- U.S. Patent 9,125,910 claims methods for treating cancers with PD-1/PD-L1 inhibitors combined with other therapeutics.
- Its claims are specific to combination regimens, limiting broad exclusivity but protecting key treatment protocols.
- The patent landscape emphasizes aggressive patenting around immunotherapy combinations, with expiration dates around 2027-2032.
- R&D pipelines should account for narrower claims related to specific combinations, dosages, or schedules.
- Licensing deals and freedom-to-operate assessments must closely examine overlap with similar combination patents.
FAQs
Q1: Are the claims in Patent 9,125,910 broad enough to cover other immunotherapy combinations?
A1: No. The claims specify particular combinations involving PD-1/PD-L1 antibodies and certain therapeutics, limiting broad coverage.
Q2: When do key patents related to PD-1/PD-L1 immunotherapy expire?
A2: Most foundational patents expire between 2027 and 2032.
Q3: Does the patent cover product claims or only method claims?
A3: Only method claims; it does not restrict the composition of matter.
Q4: How does this patent impact competitors developing similar therapies?
A4: It restricts use of specified methods involving PD-1/PD-L1 inhibitors combined with certain agents but leaves room for alternative combinations or different schedules.
Q5: Are there any known legal challenges to Patent 9,125,910?
A5: No significant invalidation or opposition has been filed, indicating the patent’s current enforceability.
References
- United States Patent and Trademark Office. (2015). Patent 9,125,910.
- Lian, T., et al. (2016). Immunotherapy patents landscape: Emerging trends and strategic considerations. Nature Reviews Drug Discovery, 15(9), 684-703.
- World Intellectual Property Organization. (2022). The patent landscape of immuno-oncology. [Data report].
- U.S. Patent and Trademark Office. (2022). Patent expiry dates and legal status data.
- European Patent Office. (2021). Trends in PD-1/PD-L1 patent filings.
More… ↓
⤷ Start Trial
|
